177Lu-HX02

N/A

Report date: 2026/04/06 20:01:48
NME

Base Information

Drug Name177Lu-HX02
Drug Alias Name177Lu-HX02177Lu-HX-02
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionIntegrin alpha-V/beta-3 modulatorsAminopeptidase N modulatorsPositron-emission tomography enhancers
TargetsIntegrin alpha-V/beta-3Aminopeptidase N
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHexin (Suzhou) Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHexin (Suzhou) Pharmaceutical Technology Co LtdHexin (Heze) Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A